Medincell SA
Research Medincell SA (MEDCL) on Bullrun: market cap EUR 970.85M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerMEDCL
- ExchangePA
- CountryFrance
- SectorHealthcare
- IndustryBiotechnology
- CurrencyEUR
- Market capEUR 970.85M
- Financial periodFY2025
- RevenueEUR 25.54M
- Revenue growth178.8%
- Net income-EUR 18.44M
- Free cash flowEUR 17.81M
- Gross margin100.0%
Valuation Snapshot
latest market cap is EUR 970.85M.
About Medincell SA
MedinCell S.A., a clinical-stage and commercial biopharmaceutical licensing company, develops long acting injectables in various therapeutic areas in France. The company develops solutions based on BEPO, a long-acting injectable technology. It offers UZEDY (mdc-IRM) for the treatment of schizophrenia in adults and bipolar I disorder. It is also developing mdc-TJK, a subcutaneous injection that is in the NDA preparation stage for the treatment of schizophrenia in adults;
Frequently asked questions
What is Medincell SA's market cap?
Medincell SA's market capitalization is EUR 970.85M.
What does Medincell SA do?
MedinCell S.A., a clinical-stage and commercial biopharmaceutical licensing company, develops long acting injectables in various therapeutic areas in France. The company develops solutions based on BEPO, a long-acting injectable technology.